

STELIS BIOPHARMA MALAYSIA SDN BHD
BALANCE SHEET AS AT MARCH 31, 2022

		Amount in MYR 31-Mar-22	Amount in MYR 31-Mar-21
A ASSETS			
I Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	4,197	897
(ii) Other financial assets	2	5,191,521	5,099,096
Total current assets		5,195,718	5,099,993
TOTAL ASSETS		5,195,718	5,099,993
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	3	13,282,094	13,282,094
(b) Other equity	4	(8,110,831)	(8,186,102)
Total Equity		5,171,263	5,095,992
II Liabilities			
1 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	5	17,954	-
(b) Other current liabilities	6	6,501	4,001
Total current liabilities		24,455	4,001
TOTAL EQUITY AND LIABILITIES		5,195,718	5,099,993

STELIS BIOPHARMA MALAYSIA SDN BHD
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2022

Particulars	Note No.	Amount in MYR	Amount in MYR
		31-Mar-22	31-Mar-21
1 Revenue from operations		-	-
2 Other Income	7	102,138	4
3 Total Revenue (1+2)		102,138	4
4 Expenses			
(a) Finance costs	8	42	97
(b) Other expenses	9	26,825	267,581
Total expenses		26,867	267,679
5 Profit / (Loss) before exceptional items and taxes (3-4)		75,271	(267,674)
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		75,271	(267,674)
8 Tax Expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
9 Profit / (Loss) for the year after tax		75,271	(267,674)

STELIS BIOPHARMA MALAYSIA SDN BHD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2022

(A) Equity share capital

Particulars	Amount in MYR
Balance as at March 31, 2021	13,282,094
Changes in equity share capital during the year	-
Balance as at March 31, 2022	13,282,094

(B) Other equity

Amount in MYR

Particulars	Securities Premium	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2021	-	(8,186,102)	-	(8,186,102)
Profit/loss for the year	-	75,271	-	75,271
Balance as at March 31, 2022	-	(8,110,831)	-	(8,110,831)

STELIS BIOPHARMA MALAYSIA SDN BHD

Notes forming part of financial statement

Note

No.

1	Cash and cash equivalents	Amount in MYR	
	Particulars	31-Mar-22	31-Mar-21
	Balances with banks:		
	In current accounts	4,197	897
	Total	4,197	897
2	Other financial assets	Amount in MYR	
	Particulars	31-Mar-22	31-Mar-21
	Advances to related parties	5,191,521	5,099,096
	Total	5,191,521	5,099,096
3	Share capital	Amount in MYR	
	Particulars	31-Mar-22	31-Mar-21
	Issued, subscribed and fully paid-up		
	Equity share capital	13,282,094	13,282,094
	Total	13,282,094	13,282,094
4	Reserves and surplus	Amount in MYR	
	Particulars	31-Mar-22	31-Mar-21
	Surplus in statement of profit and loss		
	Opening balance	(8,186,102)	(7,918,525)
	Add: Profit / (Loss) for the year	75,271	(267,577)
	Closing balance	(8,110,831)	(8,186,102)
	Total	(8,110,831)	(8,186,102)
5	Trade payables	Amount in MYR	
	Particulars	31-Mar-22	31-Mar-21
	Trade payable	17,954	-
	Total	17,954	-
6	Other current liabilities	Amount in MYR	
	Particulars	31-Mar-22	31-Mar-21
	Provision for expenses	6,501	4,001
	Total	6,501	4,001

STELIS BIOPHARMA MALAYSIA SDN BHD
Notes forming part of financial statement

Note

No.

7 Other Income	Amount in MYR	
Particulars	31-Mar-22	31-Mar-21
Exchange fluctuation gain	102,138	-
Interest Income	-	4
Total	102,138	4

8 Finance cost	Amount in MYR	
Particulars	31-Mar-22	31-Mar-21
Bank charges	42	97
Total	42	97

9 Other expenses	Amount in MYR	
Particulars	31-Mar-22	31-Mar-21
Rates & Taxes	133	495
Printing & Stationery	25,100	5,792
Conveyance & Travelling	50	-
Director sitting fees	-	6,360
Net loss on foreign currency transactions	-	252,759
Professional fees	42	675
Payment to Auditors - For Statutory Audit	1,500	1,500
Total	26,825	267,581